ClinicalTrials.gg
CompletedNCT02545452Updated Jul 24, 2017

Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring

A Phase 1 interventional study of Anastrozole / Levonorgestrel (BAY98-7196) and Gyno-Daktarin in Endometriosis, sponsored by Bayer. Completed at 1 site in Germany. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-24.

Sponsored by Bayer · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Endometriosis by Bayer — none open to participants now, none under way, none of them phase 3. Endometriosis · Bayer.

Enrollment
12th of 20
52 · median 68
Started
2015
with 2 others
Phase 1
10 of 27
none open now
Registered
13th of 27
by date

Among the 27 studies in Endometriosis by Bayer, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2015, is one of 10 in phase 1, and was the 13th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 27 studies in Endometriosis by Bayer is open now. The open studies under Endometriosis, anywhere →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Endometriosis by Bayer as a file.
02

Study summary

To investigate the pharmacokinetic effect of a vaginally administered antimycotic (miconazole), antibiotic (clindamycin), spermicide (nonoxynol-9) or the concomitant use of tampons during the use of an intravaginal ring releasing anastrozole and levonorgestrel

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy pre-menopausal female subject.
  • Age: 18 - 50 years (inclusive) at the first screening visit. For the subject > 45 years follicle stimulating hormone (FSH) will be investigated at the second screening visit to confirm the pre-menopausal status (FSH \< 40 IU/L in serum).
  • (BMI ) above or equal 18, and below or equal 30 kg / m² at the first screening visit.
  • Adequate venous access.
  • Ability to understand and follow study-related instructions
  • Agreement to use adequate non-hormonal .
  • Confirmation of the subject's health insurance coverage prior to the first screening examination/visit.

Exclusion criteria

Exclusion Criteria:

  • Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal.
  • Thrombophlebitis, venous / arterial thromboembolic diseases (particularly deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction).
  • Presence or history of prodromata of thrombosis (e.g. , angina pectoris).
  • Known to the study medications (active substances or of the preparations).
  • Regular intake of medication other than hormonal .
  • Use of systemic or topical medication or substances which oppose the study objectives or which might influence them within 4 weeks before first administration of the study medication,
  • Smoking of more than 10 cigarettes daily; if the subject is a smoker: subject is older than 35 years
  • Suspicion of or known current drug, medicine or alcohol abuse (including anabolics, high-dose vitamins).
  • Abnormal cervical smear
  • Previous ectopic pregnancy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    BAY98-7196

    Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)

    Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Drug: Gyno-Daktarin

  • Experimental
    Administered Antibiotic

    Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG

    Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Drug: Sobelin vaginal creme

  • Experimental
    Administered Spermicide

    Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG

    Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Drug: Patentex oval

  • Experimental
    Tampons

    Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days

    Drug: Anastrozole / Levonorgestrel (BAY98-7196) · Other: Tampon

Interventions

  • DrugAnastrozole / Levonorgestrel (BAY98-7196)

    Drug pages: Anastrozole · Levonorgestrel

    Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG

  • DrugGyno-Daktarin

    400 mg miconazole nitrate per day for 3 consecutive days

  • DrugSobelin vaginal creme

    100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days

  • 75 mg Nonoxynol-9 per day for 3 consecutive days

  • OtherTampon

    Also known as: Tampons (3 changes per day) for 3 consecutive days

06

What researchers measure

Primary outcomes

  1. Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups

    Time frame: 202-226h

  2. Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups

    Time frame: 226-298h

  3. Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for all groups

    Time frame: 226-384h

  4. Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group

    Time frame: 466-490h

  5. Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group

    Time frame: 490-562h

  6. Average concentration (Cav) anastrozole after insertion of the intra-vaginal ring for Tampon group

    Time frame: 490-648h

  7. Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups

    Time frame: 202-226h

  8. Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups

    Time frame: 226-298h

  9. Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for all groups

    Time frame: 226-384h

  10. Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group

    Time frame: 466-490h

  11. Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group

    Time frame: 490-562h

  12. Average concentration (Cav) levonorgestrel after insertion of the intra-vaginal ring for Tampon group

    Time frame: 490-648h

Secondary outcomes

  1. Maximum observed plasma concentration before co-medication or tampons (Cmax)

    Time frame: 490h

  2. Time to reach maximum observed concentration before co-medication or tampons (tmax)

    Time frame: 490h

  3. Plasma concentration 28 days after intra-vaginal ring (IVR) insertion (Treatment group D, Day 29) (C(28d))

    Time frame: 672h

  4. Plasma concentration 35 days after IVR insertion (Treatment group D, Day 36)(C(35d))

    Time frame: 840h

  5. Average concentration in the extended wearing period (Treatment D, Days 29-36 using the same IVR)

    Time frame: 672-840h

  6. Terminal half-life associated with the terminal slope after removal of IVR (t1/2)

    Time frame: Up to 6 days after IVR removal

  7. Number of participants with adverse events as a measure of safety and tolerability

    Time frame: Up to 14 days after IVR removal

07

Study locations

1 site
  • Berlin, 13353, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Mar 2016, 5 months.

Of 24 phase 1 interventional studies under Endometriosis, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 26. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2015
First posted
Sep 10, 2015
StartActual
Sep 15, 2015
Primary completionActual
Mar 14, 2016
CompletionActual
Jul 29, 2016
Last update
Jul 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02545452
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 10, 2015
Start date
Sep 15, 2015
Primary completion
Mar 14, 2016
Completion
Jul 29, 2016
Last update
Jul 24, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Levonorgestrel

Start the discussion